The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 3 , Pages 620-626.e3 , March 2008

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients

  • Raja M. Flores, MD

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
    • Corresponding Author InformationAddress for reprints: Raja M. Flores, MD, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Room C-879, New York, NY 10021.
    • ,
  • Harvey I. Pass, MD

      Affiliations

    • Department of Cardiothoracic Surgery, New York University Medical Center, New York, NY
    • ,
  • Venkatraman E. Seshan, PhD

      Affiliations

    • Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Joseph Dycoco, BA

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Maureen Zakowski, MD

      Affiliations

    • Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Michele Carbone, MD

      Affiliations

    • Department of Pathology, University of Hawaii, Honolulu, Hawaii
    • ,
  • Manjit S. Bains, MD

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY
    • ,
  • Valerie W. Rusch, MD

      Affiliations

    • Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY

Received 3 May 2007 ,Revised 13 September 2007 ,Accepted 22 October 2007.

References 

  1. Flores RM, Krug LM, Rosenzweig KE, Venkatraman E, Vincent A, Heelan R, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol. 2006;1:289–295
  2. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451–3457
  3. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results of 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–65
  4. Rusch VW, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol. 1994;12:1156–1163
  5. Richards WG, Zellos L, Bueno R, Jaklitsch MT, Jänne PA, Chirieac LR, et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561–1567
  6. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A Phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795
  7. Lee TT, Everett DL, Shu H-KG, Jahan TM, Roach M, Speight JL, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183–1189
  8. Hilaris BS, Dattatreyudu N, Kwong E, Kutcher GJ, Martini N. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 1984;10:325–331
  9. McCormack PM, Nagasaki F, Hilaris BS, Martini N. Surgical treatment of pleural mesothelioma. J Thorac Cardiovasc Surg. 1982;84:834–842
  10. Pass HI, Temeck BK, Kranda K, Thomas G, Russo A, Smith P, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1997;4:628–633
  11. Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005;23:3495–3501
  12. Allen KB, Faber LP, Warren WH. Malignant pleural mesothelioma. Extrapleural pneumonectomy and pleurectomy. Chest Surg Clin N Am. 1994;4:113–126
  13. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1991;102:1–9
  14. Stewart DJ, Martin-Ucar A, Pilling JE, Edwards JG, O'Byrne KJ, Waller DA. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg. 2004;78:245–252
  15. American Joint Committee on Cancer. In:  Greene FL,  Page DL,  Fleming ID,  Fritz AG,  Balch CM,  Haller DG, et al. editor. AJCC Cancer Staging Handbook. 6th ed.. New York: Springer-Verlag; 2002;
  16. Yajnik S, Rosenzweig KE, Mychalczak B, Krug L, Flores R, Hong L, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–1326
  17. Gupta V, Mychalczak B, Krug L, Flores R, Bains M, Rusch VW, et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63:1045–1052
  18. Battifora H, McCaughey WTE. Tumors of the Cardiovascular System. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology; 2003;
  19. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11–16
  20. Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, et al. Positron emission tomography (PET) predicts survival in malignant pleural mesothelioma (MPM). J Thorac Cardiovasc Surg. 2006;132:763–768
  21. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg. 1999;68:1799–1804
  22. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17:25–30
  23. Van Meerbeeck JP, Gaafar R, Manegold C, van Klaveren RJ, van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889
  24. Vogelzang NJ, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644

 This study was presented at the plenary session at the 2007 AATS Meeting.

 Dr Pass reports consulting fees from GlaxoSmithKline and Astra Zeneca.

PII: S0022-5223(07)01899-5

doi: 10.1016/j.jtcvs.2007.10.054

The Journal of Thoracic and Cardiovascular Surgery
Volume 135, Issue 3 , Pages 620-626.e3 , March 2008

Article Tools

* Image Usage & Resolution